Singapore: Boehringer Ingelheim has achieved positive results from the trial of afatinib in comparison to erlotinib in p...
Singapore: Novartis has partnered with UK based Mereo BioPharma to develop compounds including BPS-804, to improve bone ...
Singapore: India based Jubilant Biosys, subsidiary of Jubilant Life Sciences, and Germany based Sanofi Deutschland have ...
Singapore: Amgen decided to stop the ganitumab (AMG 479) phase III GAMMA (gemcitabine and AMG 479 in metastatic adenocar...
NASDAQ-listed Minerva Neurosciences Inc, a clinical-stage biopharmaceutical company focused on the development of therap...
Singapore: A team comprising Professor Patrick Tan from Duke-NUS Graduate Medical School (Duke-NUS) and A*STAR's Genome ...
Singapore: Clinical trial results on the safety and efficacy of delamanid, Otsuka Pharmaceutical's investigational compo...
Singapore: Recruitment of patients for CAROLINA (cardiovascular outcome study of Linagliptin versus Glimepiride in patie...
Seoul: Boehringer Ingelheim and Eli Lilly & Company have announced new data that reinforces the efficacy and tolerab...
Global biotherapeutics company CSL Behring has submitted its new drug application (NDA) to Japan's Pharmaceuticals and M...
Singapore: Boehringer Ingelheim and Korea's Hanmi Pharmaceutical have collaborated for the development and global commer...
Singapore: New Jersey's Charleston Laboratories Inc and Japanese major Daiichi Sankyo Inc have announced that the US Foo...
Singapore: Germany based complex biologics development and manufacturing specialist, ProBioGen, has proceeded on the cli...
A finding, published in the Latin American Herald Tribune, says that a genetic study of people with Down's syndrome help...
Singapore: Global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021,...
Singapore: Novartis has proceeded to acquire all remaining rights of GSK's Ofatumumab, a fully human monoclonal antibo...
Singapore: Bionomics, a biopharmaceutical company, has filed a patent application for BNC105 in combination with immune ...
Singapore: Tokyo-based Teijin Pharma, the core company of the Teijin Group's healthcare business, and Pulmagen Therapeu...
